human
TASK: Your task is to answer biomedical questions using the given abstract. Only output yes, no, or maybe as answer.
INPUT: ['To evaluate the effects of two major polymorphisms of CYP2C9, CYP2C9 3 and CYP2C9 13, on the pharmacokinetics of irbesartan in healthy Korean volunteers.', 'A single 150-mg oral dose of irbesartan was given to 28 Korean volunteers, who had different CYP2C9 genotypes (12, 10, and 6 carriers of CYP2C9 1/ 1, 1/ 3, and 1/13 genotypes respectively). Irbesartan levels were analyzed using HPLC fluorescence in plasma samples collected up to 36 h after the drug intake.', 'Compared with CYP2C9 1 homozygous subjects, not only were the maximum plasma concentrations (C(max)) of irbesartan in CYP2C9 1/ 3 and 1/ 13 subjects 1.56- and 1.50-fold higher (P\u2009=\u20090.001), but the half-lives were also 1.38- and 1.50-fold longer (P\u2009=\u20090.001). The area under the plasma concentration-time curve (AUC) was 1.64- and 1.79-fold higher (P\u2009<\u20090.001). The oral clearance of irbesartan was 39.3% and 44.0% lower in the CYP2C9 1/ 3 and 1/ 13 subjects respectively, than in the 1/ 1 subjects (P\u2009<\u20090.001). Likewise, the increases in half-life and decreases in oral clearance observed in CYP2C9 1/ 13 individuals were similar to those in participants expressing the CYP2C9 1/ 3 genotype.'] Do cYP2C9 3 and 13 alleles significantly affect the pharmacokinetics of irbesartan in healthy Korean subjects?
OUTPUT:

agent
yes
TASK: Your task is to answer biomedical questions using the given abstract. Only output yes, no, or maybe as answer.
INPUT: ['To evaluate the effects of two major polymorphisms of CYP2C9, CYP2C9 3 and CYP2C9 13, on the pharmacokinetics of irbesartan in healthy Korean volunteers.', 'A single 150-mg oral dose of irbesartan was given to 28 Korean volunteers, who had different CYP2C9 genotypes (12, 10, and 6 carriers of CYP2C9 1/ 1, 1/ 3, and 1/13 genotypes respectively). Irbesartan levels were analyzed using HPLC fluorescence in plasma samples collected up to 36 h after the drug intake.', 'Compared with CYP2C9 1 homozygous subjects, not only were the maximum plasma concentrations (C(max)) of irbesartan in CYP2C9 1/ 3 and 1/ 13 subjects 1.56- and 1.50-fold higher (P\u2009=\u20090.001), but the half-lives were also 1.38- and 1.50-fold longer (P\u2009=\u20090.001). The area under the plasma concentration-time curve (AUC) was 1.64- and 1.79-fold higher (P\u2009<\u20090.001). The oral clearance of irbesartan was 39.3% and 44.0% lower in the CYP2C9 1/ 3 and 1/ 13 subjects respectively, than in the 1/ 1 subjects (P\u2009<\u20090.001). Likewise, the increases in half-life and decreases in oral clearance observed in CYP2C9 1/ 13 individuals were similar to those in participants expressing the CYP2C9 1/ 3 genotype.'] Do cYP2C9 3 and 13 alleles significantly affect the pharmacokinetics of irbesartan in healthy Korean subjects?
OUTPUT:
